UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?

PloS one, 2023-02, Vol.18 (2), p.e0281726-e0281726

2023

Volltextzugriff (PDF)

Non-invasive cardiac stress studies may not offer significant benefit in pre-kidney transplant evaluation: A retrospective cohort study

PloS one, 2020-10, Vol.15 (10), p.e0240912-e0240912

2020

Volltextzugriff (PDF)

Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen

Glomerular diseases, 2023-01, Vol.3 (1), p.88-97

2023

Volltextzugriff (PDF)

The Significance of Anti-PLA2R in Diabetic Kidney Disease: Truly a False Positive?

Glomerular diseases, 2024-04, Vol.4 (1), p.91-94

2024

Volltextzugriff (PDF)

Long-term outcomes of persistent disease and relapse in primary membranous nephropathy

Nephrology, dialysis, transplantation, 2016-12, Vol.31 (12), p.2108-2114

2016

Volltextzugriff (PDF)

Prospective study of the effect of rituximab on kidney function in membranous nephropathy

Clinical kidney journal, 2024-08, Vol.17 (8), p.sfae179

2024

Volltextzugriff (PDF)

A Case of IgG4-Related Disease and Membranous Nephropathy Associated with Thrombospondin Type-1 Domain-Containing 7A

Glomerular diseases, 2022-07, Vol.2 (3), p.139-144

2022

Volltextzugriff (PDF)

Membranous nephropathy in the UK Biobank

PloS one, 2023-04, Vol.18 (4), p.e0281795-e0281795

2023

Volltextzugriff (PDF)

Utility of MEST and MEST-C Scoring in IgA Nephropathy in Kidney Transplantation: A Mini Review

OBM Transplantation, 2023-10, Vol.7 (4), p.1-13

2023

Volltextzugriff (PDF)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis

Oxford Medical Case Reports, 2022-12, Vol.2022 (12), p.omac133

2022

Volltextzugriff (PDF)

Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New‐incident and relapsing primary membranous nephropathy

Nephrology (Carlton, Vic.), 2018-01, Vol.23 (1), p.60-68

2018

Volltextzugriff (PDF)

PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy

Kidney international reports, 2023-08, Vol.8 (8), p.1605-1615

2023

Volltextzugriff (PDF)

The 13th International Podocyte Conference

Glomerular diseases, 2022-06, Vol.2 (Suppl 1), p.1-78

2022

Volltextzugriff (PDF)

Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications

Glomerular diseases, 2023-10, Vol.3 (1), p.266-274

2023

Volltextzugriff (PDF)

MO868CLINICAL OUTCOMES FOR INTRAVENOUS DRUG USERS REQUIRING HAEMODIALYSIS

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

MO321THE USE OF INTRAVENOUS CYCLOPHOSPHAMIDE AND ORAL STEROIDS IN PRIMARY MEMBRANOUS NEPHROPATHY WITH ADVANCED KIDNEY DISEASE

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

P0412VALUE OF INTERNATIONAL RISK-PREDICTION TOOL IN IGA NEPHROAPTHY : A SINGLE CENTRE STUDY

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

Review of plasma exchange and rituximab for prevention of recurrent focal segmental glomerulosclerosis after a prior graft loss

World journal of transplantation, 2024-12, Vol.14 (4)

2024

Volltextzugriff (PDF)

Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model

Nephrology, dialysis, transplantation, 2018-12, Vol.33 (12), p.2145-2155

2018

Volltextzugriff (PDF)

Can use of the serum anti-PLA.sub.2R antibody negate the need for a renal biopsy in primary membranous nephropathy?

PloS one, 2023-02, Vol.18 (2), p.e0281726

2023

Volltextzugriff (PDF)

6211 THE OPPORTUNITY COSTS EXPERIENCED BY PATIENTS WHO INJECT DRUGS UNDERGOING HAEMODIALYSIS: A CASE SERIES

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection

World journal of transplantation, 2023-12, Vol.13 (6), p.299-308

2023

Volltextzugriff (PDF)

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy

Kidney international, 2013-05, Vol.83 (5), p.940-948

2013

Volltextzugriff (PDF)

Time for a relook? An update on primary membranous nephropathy incidence in a large UK cohort

Clinical kidney journal, 2024-04, Vol.17 (4), p.sfae066-sfae066

2024

Volltextzugriff (PDF)

Impact of Time to Treatment on Outcomes in Primary Membranous Nephropathy: SA-PO914

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.983-983

2023

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(47)
Berichte
(1)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(14)
Humans
(10)
Urology & Nephrology
(10)
Adult
(7)
Membranous Nephropathy
(7)
Nephrotic Syndrome
(7)
Diagnosis
(6)
Female
(6)
Male
(6)
Middle Aged
(6)
Kidney Diseases
(5)
Treatment Outcome
(5)
Autoantibodies - Blood
(4)
Biomarkers
(4)
Biopsy
(4)
Complications And Side Effects
(4)
Enzyme-Linked Immunosorbent Assay
(4)
Glomerulonephritis, Membranous - Therapy
(4)
Nephropathy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?

Non-invasive cardiac stress studies may not offer significant benefit in pre-kidney transplant evaluation: A retrospective cohort study

Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen

The Significance of Anti-PLA2R in Diabetic Kidney Disease: Truly a False Positive?

Long-term outcomes of persistent disease and relapse in primary membranous nephropathy

Prospective study of the effect of rituximab on kidney function in membranous nephropathy

A Case of IgG4-Related Disease and Membranous Nephropathy Associated with Thrombospondin Type-1 Domain-Containing 7A

Membranous nephropathy in the UK Biobank

Utility of MEST and MEST-C Scoring in IgA Nephropathy in Kidney Transplantation: A Mini Review

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis

Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New‐incident and relapsing primary membranous nephropathy

PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy

The 13th International Podocyte Conference

Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications

MO868CLINICAL OUTCOMES FOR INTRAVENOUS DRUG USERS REQUIRING HAEMODIALYSIS

MO321THE USE OF INTRAVENOUS CYCLOPHOSPHAMIDE AND ORAL STEROIDS IN PRIMARY MEMBRANOUS NEPHROPATHY WITH ADVANCED KIDNEY DISEASE

P0412VALUE OF INTERNATIONAL RISK-PREDICTION TOOL IN IGA NEPHROAPTHY : A SINGLE CENTRE STUDY

Review of plasma exchange and rituximab for prevention of recurrent focal segmental glomerulosclerosis after a prior graft loss

Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model

Can use of the serum anti-PLA.sub.2R antibody negate the need for a renal biopsy in primary membranous nephropathy?

6211 THE OPPORTUNITY COSTS EXPERIENCED BY PATIENTS WHO INJECT DRUGS UNDERGOING HAEMODIALYSIS: A CASE SERIES

Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy

Time for a relook? An update on primary membranous nephropathy incidence in a large UK cohort

Impact of Time to Treatment on Outcomes in Primary Membranous Nephropathy: SA-PO914

Suchergebnisse filtern